受试者招募

订阅

MedSci主页 / 所有栏目 / 受试者招募

招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究

2015-09-09 MedSci MedSci原创

吡咯替尼乳腺癌
关注

1.  试验药物简介 吡咯替尼是EGFR/HER2/c-Src抑制剂，本试验的适应症是HER2表达阳性转移性乳腺癌。   2. 试验目的 比较吡咯替尼联合卡培他滨方案及拉帕替尼联合卡培他滨方案治疗HER2表达阳性转移性乳腺癌的安全性和有效性。   3.试验设计 试验分类：安全性和有效性 试验分期：其它 设计类型：平行分组（试验组：吡咯替尼+卡培他滨，

1.  试验药物简介
吡咯替尼是EGFR/HER2/c-Src抑制剂，本试验的适应症是HER2表达阳性转移性乳腺癌。
 
2. 试验目的
比较吡咯替尼联合卡培他滨方案及拉帕替尼联合卡培他滨方案治疗HER2表达阳性转移性乳腺癌的安全性和有效性。
 
3.试验设计
试验分类：安全性和有效性
试验分期：其它
设计类型：平行分组（试验组：吡咯替尼+卡培他滨，对照组：拉帕替尼+卡培他滨）
随机化： 随机化
盲法：  开放
试验范围：国内试验
入组人数：    128人

4.入选标准
1年龄为18～70岁（包括18岁和70岁）；
2ECOG全身状态（performancestatus，PS）0～1级；
3预计生存期不少于12周；
4患者至少有一个可测量病灶存在（RECIST 1.1）；
5组织学或细胞学检查证实的HER2表达阳性晚期乳腺癌患者（HER2表达阳性指不少于10%的肿瘤细胞免疫组化染色强度为2＋且经荧光原位杂交技术[FISH]确认阳性者，或免疫组化染色强度为3＋[染色强度范围0～3]）；
6接受过蒽环类和紫杉类药物治疗失败，且复发/转移后化疗不超过2线的患者，既往可以用过或未用过靶向HER2的大分子抗体；
7器官的功能水平必须符合下列要求：ANC≥1.5×109/L；PLT≥90×109/L；Hb≥90 g/L；TBIL≤1.5×ULN；ALT和AST≤1.5×ULN；对于有肝转移灶者，ALT和AST≤5×ULN； BUN和Cr≤1×ULN且肌酐清除率≥50 mL/min（Cockcroft-Gault公式）。 LVEF≥50%；Fridericia法校正的QT间期（QTcF）男性 < 450 ms、女性 < 470 ms；
8自愿加入本研究，签署知情同意，有良好的依从性并愿意配合随访。
 
5.排除标准
1存在无法通过引流或其他方法控制的第三间隙积液（如大量胸水和腹水）；
2无法吞咽、慢性腹泻和肠梗阻，存在影响药物服用和吸收的多种因素；
3入组前4周内接受过放疗、化疗、激素治疗、手术或分子靶向治疗者；入组前6周内接受过亚硝基脲或丝裂霉素化疗；
4入组前4周内参加过其它药物临床试验；
5入组前6个月内使用过卡培他滨，对卡培他滨既往无效（包括卡培他滨治疗中进展，或治疗后临床疗效维持时间<3个月）或不能耐受卡培他滨者；
6经颅脑CT或MRI检查确诊，存在脑部肿瘤病灶者；
7既往使用或正在使用以HER2为靶点的酪氨酸激酶抑制剂（包括拉帕替尼，来那替尼及吡咯替尼等）；
8既往5年内患有其他肿瘤，不包括已治愈的宫颈原位癌、皮肤基底细胞癌或皮肤鳞状细胞癌；
9 同时接受其他任何抗肿瘤治疗；
10过敏体质者，或已知对本方案药物组分有过敏史者；
11 已知二氢嘧啶脱氢酶（DPD）缺陷的患者；
12有免疫缺陷病史，包括HIV检测阳性，或患有其他获得性、先天性免疫缺陷疾病，或有器官移植史；
13曾患有任何心脏疾病，包括：（1）心绞痛；（2）需药物治疗的或有临床意义的心律失常；（3）心肌梗死；（4）心力衰竭；（5）任何被研究者判断为不适于参加本试验的其他心脏疾病等；
14妊娠期、哺乳期女性患者，有生育能力且基线妊娠试验检测阳性的女性患者或在整个试验期间不愿意采取有效避孕措施的育龄女性患者；
15根据研究者的判断，有严重的危害患者安全、或影响患者完成研究的伴随疾病（包括但不限于高血压、严重的糖尿病、活动性感染、甲状腺疾病等）；
16有酗酒、吸烟等不良嗜好（研究者判断）；
17既往有明确的神经或精神障碍史，包括癫痫或痴呆；

6. 主要研究者信息

姓名

徐兵河

职称

主任医师，教授

电话

010-87788114

Email

xubinghe@medmail.com.cn

邮政地址

北京朝阳区潘家园南里17号

邮编

100021

单位名称

中国医学科学院肿瘤医院

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649965, encodeId=aed3164996571, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Wed Feb 03 20:08:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652737, encodeId=355b1652e3707, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Apr 18 01:08:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386168, encodeId=fcd513861684c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441533, encodeId=4d371441533f1, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524573, encodeId=7a8715245e3e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548484, encodeId=d612154848448, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
    2016-02-03 huiwelcome

    #II期临床研究#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1649965, encodeId=aed3164996571, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Wed Feb 03 20:08:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652737, encodeId=355b1652e3707, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Apr 18 01:08:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386168, encodeId=fcd513861684c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441533, encodeId=4d371441533f1, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524573, encodeId=7a8715245e3e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548484, encodeId=d612154848448, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
    2016-04-18 医生2402

    #I期临床#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1649965, encodeId=aed3164996571, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Wed Feb 03 20:08:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652737, encodeId=355b1652e3707, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Apr 18 01:08:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386168, encodeId=fcd513861684c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441533, encodeId=4d371441533f1, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524573, encodeId=7a8715245e3e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548484, encodeId=d612154848448, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
    2015-09-11 w363522449

    #卡培他滨#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1649965, encodeId=aed3164996571, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Wed Feb 03 20:08:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652737, encodeId=355b1652e3707, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Apr 18 01:08:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386168, encodeId=fcd513861684c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441533, encodeId=4d371441533f1, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524573, encodeId=7a8715245e3e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548484, encodeId=d612154848448, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
    2015-09-11 1249842em09(暂无昵称)

    #转移性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1649965, encodeId=aed3164996571, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Wed Feb 03 20:08:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652737, encodeId=355b1652e3707, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Apr 18 01:08:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386168, encodeId=fcd513861684c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441533, encodeId=4d371441533f1, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524573, encodeId=7a8715245e3e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548484, encodeId=d612154848448, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
    2015-09-11 ms9474365431325850

    #拉帕替尼#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1649965, encodeId=aed3164996571, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Wed Feb 03 20:08:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652737, encodeId=355b1652e3707, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Apr 18 01:08:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386168, encodeId=fcd513861684c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441533, encodeId=4d371441533f1, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524573, encodeId=7a8715245e3e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548484, encodeId=d612154848448, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
    2015-09-11 guihongzh

    #II期临床#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1649965, encodeId=aed3164996571, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Wed Feb 03 20:08:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652737, encodeId=355b1652e3707, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Apr 18 01:08:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293496, encodeId=00f81293496b5, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386168, encodeId=fcd513861684c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441533, encodeId=4d371441533f1, content=<a href='/topic/show?id=1b785613921' target=_blank style='color:#2F92EE;'>#拉帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56139, encryptionId=1b785613921, topicName=拉帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7acb4863797, createdName=ms9474365431325850, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524573, encodeId=7a8715245e3e7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548484, encodeId=d612154848448, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Fri Sep 11 13:08:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
    2015-09-11 ms1260584454294838

    #招募#

    0